Mesoblast Ltd (MESO) stock analysis
Close on Nov 11, 2026Market cap $1.77BP/E –Yield –
StockData Score
Prices as of Nov 11, 2026How the score works
Weak6 of 30 checks passed
Mesoblast passes 6 of the 30 checks behind our score; 22 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 0/6
- Growth
- 3/6
- Past performance
- 2/6
- Financial health
- 1/6
- Dividend
- 0/6
What stands out
Revenue growing 10%+ a year
Revenue grew 152% a year over the last three fiscal years.
Growing faster than the industry
Revenue grew 599% over the last twelve months; the Drugs median is 8.0%.
Gross margin improving
Gross margin was 86.1% over the last twelve months, against 70.2% a year earlier.
Net margin above its 5-year average
Net margin was -47.8% over the last twelve months, against a 5-year average of -824%.
What to watch
Debt not well covered by cash flow
Operating cash flow over the last twelve months equals -33.8% of total debt; we look for at least 20%.
No dividend
Mesoblast has not paid a dividend in the last twelve months.
Valuation0/6
P/E against its history
Not enough price and earnings history to compare.
P/E against the industry
Needs positive earnings and enough profitable companies in the industry.
EV/EBITDA against its history
Needs positive EBITDA and price history.
P/B against the industry
Needs positive book value.
Price against fair value
We could not estimate a fair value: it needs at least two valuation methods with positive inputs.
Margin of safety
Depends on the fair value estimate.
Growth3/6
Revenue growing 10%+ a year
Revenue grew 152% a year over the last three fiscal years.
EPS growth over 3 years
Needs positive EPS three years ago and today.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growing faster than the industry
Revenue grew 599% over the last twelve months; the Drugs median is 8.0%.
Guidance issued
The latest outlook (full-year fiscal 2026 Ryoncil® net revenue, Feb 27, 2026) was issued for the first time, so it neither adds nor takes away points.
Gross margin improving
Gross margin was 86.1% over the last twelve months, against 70.2% a year earlier.
Past performance2/6
Return on equity
Needs positive equity and five years of results.
Return on invested capital
Needs operating income and invested capital.
Return on equity against the industry
Needs positive equity.
Earnings over 5 years
Needs positive net income five years ago and in the latest year.
Net margin above its 5-year average
Net margin was -47.8% over the last twelve months, against a 5-year average of -824%.
Net margin above the industry
Mesoblast's net margin of -47.8% is above the Drugs median of -53.0%.
Financial health1/6
Debt level
Needs debt and equity figures.
Debt trend
Needs a balance sheet from five years ago with positive equity.
Debt not well covered by cash flow
Operating cash flow over the last twelve months equals -33.8% of total debt; we look for at least 20%.
Interest coverage
Interest expense is not reported separately.
Short-term assets cover short-term debts
Current assets are 2.43 times current liabilities.
Bankruptcy risk (Altman Z)
Needs market value, working capital and retained earnings.
Dividend0/6
No dividend
Mesoblast has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itWe don't publish a fair value for Mesoblast. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
Medium risk
- Average value traded per day
- $3.89M
- Value traded per 1% price move
- $1.16M
Downside
Medium risk
- Typical loss in a bad month
- 19.1%
- Volatility (annualized)
- 57%
- Sharpe ratio, 1 year
- -0.26
- Beta to the S&P 500 (5Y)
- 1.51
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2015 to 2026
Gross margin
Net margin
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +599.2% | +152.1% | +74.5% | +10.9% | |
| Gross profit | +758.3% | +139.9% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on assets | – | -13.4% | -7.4% | |
| Current ratio | 1.73 | 1.57 | 2.43 | |
| Inventory turnover | – | – | 0.7× | |
| Capex to revenue | – | – | 0.7% | |
| Diluted shares | 399M | 605M | 1.29B |
Cash use needs five years of cash flow figures
Mesoblast does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
- ProfitableNet income above zero-$57.50M
- Cash generatingOperating cash flow above zero-$43.83M
- Return on assets improvedROA up on the prior year-15.3% → -7.3%
- Earnings backed by cashOperating cash flow above net income-$43.83M vs -$57.50M
- Less leverageLong-term debt to assets fell8.6% → 14.1%
- Better liquidityCurrent ratio rose1.99 → 2.43
- No dilutionShare count did not rise1.21B → 1.29B
- Gross margin improvedGross margin up on the prior year70.17% → 86.14%
- More efficientAsset turnover rose0.03 → 0.15
See a number that looks wrong?